Acotec Scientific Holdings Limited (HK:6669) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Acotec Scientific Holdings Limited has received approval from the PRC National Medical Products Administration for its Paclitaxel-Eluting Coronary Balloon Dilatation Catheter, AcoArt Camellia. Clinical trials demonstrated its superior efficacy and safety for treating coronary artery lesions compared to control groups. The company plans to launch marketing activities in China when appropriate.
For further insights into HK:6669 stock, check out TipRanks’ Stock Analysis page.